H.C. Wainwright reiterates Buy rating on Rein Therapeutics stock at $10

Published 23/09/2025, 12:48
H.C. Wainwright reiterates Buy rating on Rein Therapeutics stock at $10

Investing.com - H.C. Wainwright has reiterated its Buy rating and $10.00 price target on Rein Therapeutics (NASDAQ:RNTX) stock, maintaining a significantly bullish outlook despite the current share price of $1.21. The stock has faced significant headwinds, down 48.7% year-to-date and 68.2% over the past year, according to InvestingPro data.

The research firm expressed optimism regarding updated information that could potentially lead to lifting the pause on U.S. clinical trial sites, describing this development as "supportive of a path" forward.

H.C. Wainwright’s analysis assumes either the U.S. pause will be lifted or that ex-U.S. sites will generate sufficient data to meet the anticipated 2026 data readout timeline.

The firm recently initiated coverage on Rein Therapeutics based on its view that the stock remains undervalued relative to the potential of its lead program LTI-03 in idiopathic pulmonary fibrosis (IPF).

According to H.C. Wainwright, LTI-03 offers a differentiated dual mechanism of action that includes both fibrosis inhibition and epithelial regeneration, supported by what the firm describes as "compelling early biomarker data."

In other recent news, Rein Therapeutics has reported positive data for its lead drug candidate LTI-03, showing promising anti-fibrotic activity in lung tissue from patients with idiopathic pulmonary fibrosis (IPF). This development was published in the peer-reviewed journal iScience, highlighting the drug’s potential to reduce scarring pathways and lower collagen production. Additionally, the UK Medicines and Healthcare products Regulatory Agency has approved the Phase 2 RENEW clinical trial for LTI-03, which will assess safety and tolerability in up to 120 patients worldwide. In financial developments, Rein Therapeutics has secured up to $21 million in strategic financing from Yorkville Advisors Global, LP, to support its clinical programs. This includes a $6 million pre-paid advance agreement and a $15 million standby equity purchase agreement. On the analyst front, H.C. Wainwright has initiated coverage on Rein Therapeutics with a Buy rating, citing its potential best-in-class pipeline. However, Brookline Capital Markets downgraded the stock to Hold due to concerns over clinical trial delays and funding challenges. These recent developments provide a comprehensive view of Rein Therapeutics’ current activities and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.